U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Globe Newswire•26/08/2026•12:59 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.